Sirnaomics said this week that it has signed a deal with an undisclosed Chinese pharmaceutical company to co-develop an siRNA-based drug for scarless wound healing.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

The new alliance "provides financial resources and local capabilities allowing acceleration through the clinical study and regulatory process in China," the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.